Tandem Diabetes files Rule 144 to sell 361 shares
Tandem Diabetes Care submitted a Rule 144 notice to sell 361 shares of its common stock represented by Restricted Stock Units, with an issuer-designated sale method dated 06/15/2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Tandem Diabetes Care submitted a Rule 144 notice to sell 361 shares of its common stock represented by Restricted Stock Units, with an issuer-designated sale method dated 06/15/2026.
Separately, the filing discloses a 10b5-1 sale by Mark Novara of 266 shares on 05/19/2026, reported in the "Securities Sold During The Past 3 Months" section. The filing lists broker details as Morgan Stanley Smith Barney LLC.
Insights
Rule 144 notice lists 361 RSU-based common shares to be sold; prior 10b5-1 sale of 266 shares is disclosed.
Rule 144 forms are procedural notices that specify proposed resale of restricted or control securities under resale conditions. This filing identifies 361 shares tied to Restricted Stock Units with an issuer-designated disposition method dated 06/15/2026.
Documented prior activity includes a 10b5-1 sale by Mark Novara of 266 shares on 05/19/2026. Subsequent filings or confirmations will show actual sale execution and any proceeds; timing and cash-flow treatment are not detailed here.
Key Figures
Key Terms
Rule 144 regulatory
Restricted Stock Units financial
10b5-1 regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does Tandem Diabetes Care's (TNDM) Rule 144 filing report?
What brokerage is listed for the proposed TNDM resale under Rule 144?
AI-generated analysis. How Rhea-AI works. Not financial advice.